PriceTargets.com logo

VanEck Bionic Engineering UCITS ETF - CYBG Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 0 As of 03/30/2023 10:00 PM ET
+0 (0.00%)

This chart shows the closing price for CYBG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New VanEck Bionic Engineering UCITS ETF Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYBG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYBG

Analyst Price Target is GBX 0
This price target is based on 0 analysts offering 12 month price targets for VanEck Bionic Engineering UCITS ETF in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.

This chart shows the closing price for CYBG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in VanEck Bionic Engineering UCITS ETF. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/22/2019HSBCInitiated CoverageBuyGBX 160
10/17/2019Deutsche Bank AktiengesellschaftReiterated RatingHold
10/14/2019BarclaysReiterated RatingEqual weight
10/14/2019Jefferies Financial GroupLower TargetBuyGBX 341 ➝ GBX 189
10/1/2019BarclaysLower TargetEqual WeightGBX 180 ➝ GBX 145
9/13/2019Shore CapitalReiterated RatingBuy
9/6/2019JPMorgan Chase & Co.Lower TargetNeutralGBX 200 ➝ GBX 150
9/6/2019Deutsche Bank AktiengesellschaftLower TargetHoldGBX 220 ➝ GBX 180
9/6/2019CitigroupReiterated RatingBuyGBX 180
9/5/2019UBS GroupReiterated RatingBuyGBX 170 ➝ GBX 155
8/29/2019Royal Bank of CanadaReiterated RatingOutperformGBX 250 ➝ GBX 210
8/19/2019UBS GroupUpgradeBuyGBX 195 ➝ GBX 170
8/15/2019The Goldman Sachs GroupLower TargetNeutralGBX 250 ➝ GBX 215
7/31/2019Deutsche Bank AktiengesellschaftReiterated RatingHold
7/30/2019Jefferies Financial GroupReiterated RatingBuyGBX 341
7/30/2019Shore CapitalReiterated RatingBuy
7/29/2019UBS GroupReiterated RatingNeutral
7/26/2019Morgan StanleyBoost TargetEqual weightGBX 200 ➝ GBX 205
7/24/2019Deutsche Bank AktiengesellschaftBoost TargetHoldGBX 214 ➝ GBX 220
7/17/2019BarclaysReiterated RatingEqual weight
7/12/2019Deutsche Bank AktiengesellschaftLower TargetHoldGBX 215 ➝ GBX 214
7/1/2019Jefferies Financial GroupBoost TargetBuyGBX 285 ➝ GBX 341
6/21/2019CitigroupReiterated RatingBuyGBX 245
6/21/2019BarclaysBoost TargetEqual WeightGBX 200 ➝ GBX 210
6/20/2019UBS GroupReiterated RatingNeutralGBX 188 ➝ GBX 195
6/20/2019Royal Bank of CanadaReiterated RatingOutperformGBX 250
6/19/2019Shore CapitalReiterated RatingBuyGBX 280 ➝ GBX 265
6/5/2019Morgan StanleyLower TargetEqual WeightGBX 235 ➝ GBX 200
5/23/2019The Goldman Sachs GroupLower TargetNeutralGBX 260 ➝ GBX 250
5/10/2019UBS GroupReiterated RatingNeutral
4/23/2019UBS GroupBoost TargetNeutralGBX 193 ➝ GBX 201
4/15/2019InvestecDowngradeHoldGBX 230
4/15/2019CitigroupReiterated RatingBuyGBX 230
4/9/2019Jefferies Financial GroupLower TargetBuyGBX 366 ➝ GBX 285
3/28/2019BarclaysUpgradeEqual weightGBX 230 ➝ GBX 220
3/12/2019The Goldman Sachs GroupBoost TargetNeutralGBX 235 ➝ GBX 260
2/25/2019UBS GroupLower TargetNeutralGBX 200 ➝ GBX 193
2/22/2019Shore CapitalReiterated RatingBuy
2/12/2019Shore CapitalReiterated RatingBuy
2/11/2019UBS GroupLower TargetNeutralGBX 210 ➝ GBX 200
2/7/2019BarclaysBoost TargetUnderweightGBX 220 ➝ GBX 230
2/6/2019Shore CapitalReiterated RatingBuyGBX 320
2/5/2019Deutsche Bank AktiengesellschaftUpgradeHoldGBX 248 ➝ GBX 184
1/21/2019JPMorgan Chase & Co.Lower TargetNeutralGBX 220 ➝ GBX 200
1/7/2019UBS GroupReiterated RatingNeutral
12/18/2018JPMorgan Chase & Co.UpgradeNeutralGBX 310 ➝ GBX 220
12/13/2018BarclaysLower TargetUnderweightGBX 240 ➝ GBX 220
11/23/2018UBS GroupLower TargetNeutralGBX 273 ➝ GBX 210
11/23/2018Credit Suisse GroupUpgradeNeutralGBX 285 ➝ GBX 215
11/21/2018BarclaysLower TargetUnderweightGBX 280 ➝ GBX 240
11/19/2018Shore CapitalReiterated RatingHold
10/25/2018UBS GroupUpgradeNeutralGBX 311 ➝ GBX 273
10/23/2018BarclaysInitiated CoverageUnderweightGBX 280
10/11/2018Shore CapitalReiterated RatingHold
10/4/2018Shore CapitalReiterated RatingHold
10/2/2018UBS GroupInitiated CoverageSellGBX 311
9/17/2018Berenberg BankDowngradeHoldGBX 350
7/30/2018Shore CapitalReiterated RatingHold
7/6/2018Shore CapitalReiterated RatingHold
6/28/2018Berenberg BankReiterated RatingBuyGBX 350
6/21/2018JPMorgan Chase & Co.UpgradeNeutralGBX 270 ➝ GBX 310
6/18/2018Shore CapitalReiterated RatingHold
6/4/2018Shore CapitalReiterated RatingHold
5/16/2018JPMorgan Chase & Co.Reiterated RatingUnderweight
5/15/2018Shore CapitalReiterated RatingHold
5/8/2018Berenberg BankReiterated RatingBuyGBX 350
5/8/2018Royal Bank of CanadaReiterated RatingSector Performer
5/8/2018Shore CapitalBoost TargetHoldGBX 304 ➝ GBX 318
4/19/2018Berenberg BankLower TargetBuyGBX 375 ➝ GBX 350
4/19/2018Deutsche Bank AktiengesellschaftLower TargetSellGBX 264 ➝ GBX 248
4/18/2018Shore CapitalReiterated RatingHoldGBX 304
4/5/2018Berenberg BankReiterated RatingBuyGBX 375
4/5/2018BNP ParibasBoost TargetNeutralGBX 280 ➝ GBX 330
4/4/2018Deutsche Bank AktiengesellschaftReiterated RatingSellGBX 281
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
VanEck Bionic Engineering UCITS ETF logo
CYBG PLC, through its subsidiaries, provides retail and business banking products and services to individuals and businesses under the Clydesdale Bank, Yorkshire Bank, B, and Virgin Money brands in the United Kingdom. It operates through SME Banking and Retail Banking segments. The SME Banking segment offers a range of banking products and services, including business current accounts; and secured and unsecured term loans, business overdrafts, and invoice and asset financing products and services. It also provides international trade services, such as import loans, export loans, documentary collections, currency guarantees, and letters of credit for securing trade; and current account facilities comprising debit cards, cheque books, regular statements, direct debits, and standing orders, as well as day to day and online banking services. This segment serves business customers in the small business, commercial, corporate, and structured finance markets. The Retail Banking segment offers personal current accounts, savings accounts, and term deposits; occupied mortgage loans and BTL loans, unsecured personal loans, and overdrafts, as well as credit card products; and insurance and investment products. The company was founded in 1838 and is based in Leeds, the United Kingdom.
Read More

Today's Range

Now: N/A

50 Day Range

MA: GBX 17.01
Low: 16.51
High: 17.79

52 Week Range

Now: N/A

Volume

100 shs

Average Volume

3,181,606 shs

Market Capitalization

£245.56 million

P/E Ratio

N/A

Dividend Yield

2.25%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of VanEck Bionic Engineering UCITS ETF?

The following Wall Street sell-side analysts have issued reports on VanEck Bionic Engineering UCITS ETF in the last twelve months:
View the latest analyst ratings for CYBG.

What is the current price target for VanEck Bionic Engineering UCITS ETF?

0 Wall Street analysts have set twelve-month price targets for VanEck Bionic Engineering UCITS ETF in the last year. has the lowest price target set, forecasting a price of £100,000 for VanEck Bionic Engineering UCITS ETF in the next year.
View the latest price targets for CYBG.

What is the current consensus analyst rating for VanEck Bionic Engineering UCITS ETF?

VanEck Bionic Engineering UCITS ETF currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CYBG.

What other companies compete with VanEck Bionic Engineering UCITS ETF?

Other companies that are similar to VanEck Bionic Engineering UCITS ETF include Metro Bank, Bank of Ireland Group, Charter Court Financial Services Grp, Witan Pacific Investment Trust PLC (WPC.L) and JPMorgan European Investment Trust Income Pool. Learn More about companies similar to VanEck Bionic Engineering UCITS ETF.

How do I contact VanEck Bionic Engineering UCITS ETF's investor relations team?

VanEck Bionic Engineering UCITS ETF's physical mailing address is 51 West George St, 40 St. Vincent Place, GLASGOW, G1 2HL, United Kingdom. The company's listed phone number is +44-141-2324763. The official website for VanEck Bionic Engineering UCITS ETF is www.cybg.com. Learn More about contacing VanEck Bionic Engineering UCITS ETF investor relations.